EGFR and lung adenocarcinoma: Studies were carried out on people with confirmed locally advanced (stage IIIB) or metastatic (stage IV) squamous and/or non-squamous types of NSCLC, with only one study focusing on advanced epidermal growth factor receptor (EGFR) + TP53 co-variant lung adenocarcinomas.